- Min.Order :100 Gram
- Purity: 99.5
- Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram,Other
Keywords
GLYX-13 GLYX-13 GLYX-13
Quick Details
- Appearance:white
- Application:
- PackAge:25/g
- ProductionCapacity:|Metric Ton|Day
- Storage:dry
- Transportation:dhl fedex
Superiority:
GLYX-13 is a partial agonist of the NMDA recept- specifically at the glycine binding site. It has been shown to enhance memory learning in both young adult learning-impaired, aging rat models. GLYX-13, a tetrapeptide (H-Thr-Pro-Pro-Thr-NH2), readily crosses the blood brain barrier has been shown to increase Schaffer collateral-CA1 LTP in vitro. In concert with a learning task it has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in 3-month-old rats. Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, dentate gyrus pyramidal neurons under glucose oxygen-deprived conditions. Preclinical data indicates that GLYX-13 has a therapeutic index of 500 more, onset within 20 minutes of administration, produces antidepressant-like effects lasting approximately two weeks following administration. Currently under development by Naurex Inc, the compound recently completed phase II trials as a treatment fthose resistant non-responsive to traditional antidepressants.
Details:
GLYX-13 is a partial agonist of the NMDA recept- specifically at the glycine binding site. It has been shown to enhance memory learning in both young adult learning-impaired, aging rat models. GLYX-13, a tetrapeptide (H-Thr-Pro-Pro-Thr-NH2), readily crosses the blood brain barrier has been shown to increase Schaffer collateral-CA1 LTP in vitro. In concert with a learning task it has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in 3-month-old rats. Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, dentate gyrus pyramidal neurons under glucose oxygen-deprived conditions. Preclinical data indicates that GLYX-13 has a therapeutic index of 500 more, onset within 20 minutes of administration, produces antidepressant-like effects lasting approximately two weeks following administration. Currently under development by Naurex Inc, the compound recently completed phase II trials as a treatment fthose resistant non-responsive to traditional antidepressants.
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View